Ligand Pipeline

Ligand Target Indication Development
BBL1010 Dopamine D2 Receptor Schizophrenia Preclinical
BBL1020 Dopamine D2 Receptor Addiction / Movement Disorders Preclinical

Innovative Ligands

BetaBlue's lead compounds, BBL1010 and BBL1020 are structurally based upon the backbone of the aripiprazole molecule and have functional bias and site-specific selectivity at dopamine D2 receptors.

This functional selectivity profile, coupled with demonstrated favorable pharmacokinetic properties in vivo suggests that these compounds may yield distinct advantages as candidate pharmaceuticals in the treatment of a number of dopamine D2 receptor associated illnesses.

Our lead compound, BBL1010 is being developed as a therapeutic to treat schizophrenia. Another lead ligand, BBL1020, is being developed to treat addiction and dopamine-related movement disorders such as dyskinesia associated with the treatment of Parkinson's disease, Huntington's disease and certain dystonias.